DISCOntinuation VERsus continuation of antiarrhythmic drugs prior to Pulmonary Vein Isolation for atrial fibrillation and influence on dormant conduction with adenosine; a randomised controlled trial.
- Conditions
- Atrial fibrillationAntiarrhythmic drugs AADDormant conductionPulmonary Vein IsolationPVICatheter ablationCryoballoonRadiofrequentAtriumfibrillerenBoezemfibrillerenAnti-aritmica
- Registration Number
- NL-OMON29546
- Lead Sponsor
- MST Enschede
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 188
Inclusion Criteria
Adults with atrial fibrillation EHRA class II or higher during therapy with class I or III (excluding amiodaron) antiarrhythmic drugs eligible for PVI.
Exclusion Criteria
-Usage of amiodaron (due to very long half life time(20-100 days) these patients will be excluded)
-Prior PVI or MAZE
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of dormant conduction with adenosine challenge after initial successful PVI.
- Secondary Outcome Measures
Name Time Method 1. Incidence of AF during cessation of AAD drugs. <br /><br>2. Recurrence of AF within 12 months of the procedure on ECG or >30 seconds on Holter/Vitaphone (With applied blanking period of 3 months)<br>